N-[O-Phosphono-Pyridoxyl]-Isoleucine

Identification

Name
N-[O-Phosphono-Pyridoxyl]-Isoleucine
Accession Number
DB02635  (EXPT01863)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 362.3154
Monoisotopic: 362.124287612
Chemical Formula
C14H23N2O7P
InChI Key
GZZDWFDWHXPWJK-QPUJVOFHSA-N
InChI
InChI=1S/C14H23N2O7P/c1-4-8(2)12(14(18)19)16-6-11-10(7-23-24(20,21)22)5-15-9(3)13(11)17/h5,8,12,16-17H,4,6-7H2,1-3H3,(H,18,19)(H2,20,21,22)/t8-,12+/m0/s1
IUPAC Name
(2R,3S)-2-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]-3-methylpentanoic acid
SMILES
[H][[email protected]](C)(CC)[[email protected]@]([H])(NCC1=C(COP(O)(O)=O)C=NC(C)=C1O)C(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UBranched-chain-amino-acid aminotransferase, mitochondrialNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
92282619
PubChem Substance
46508097
ChemSpider
26326995
HET
ILP
PDB Entries
1kt8 / 5wyf

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.691 mg/mLALOGPS
logP-0.15ALOGPS
logP-2.8ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)1.19ChemAxon
pKa (Strongest Basic)10.25ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area149.21 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity85.59 m3·mol-1ChemAxon
Polarizability34.51 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9463
Blood Brain Barrier-0.8309
Caco-2 permeable-0.6532
P-glycoprotein substrateSubstrate0.6502
P-glycoprotein inhibitor INon-inhibitor0.7836
P-glycoprotein inhibitor IINon-inhibitor0.936
Renal organic cation transporterNon-inhibitor0.9433
CYP450 2C9 substrateNon-substrate0.7817
CYP450 2D6 substrateNon-substrate0.786
CYP450 3A4 substrateNon-substrate0.5888
CYP450 1A2 substrateNon-inhibitor0.7439
CYP450 2C9 inhibitorNon-inhibitor0.7694
CYP450 2D6 inhibitorNon-inhibitor0.8393
CYP450 2C19 inhibitorNon-inhibitor0.6961
CYP450 3A4 inhibitorNon-inhibitor0.7777
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9042
Ames testNon AMES toxic0.6833
CarcinogenicityNon-carcinogens0.8378
BiodegradationNot ready biodegradable0.9508
Rat acute toxicity2.4958 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8187
hERG inhibition (predictor II)Non-inhibitor0.562
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridoxamine 5'-phosphates. These are heterocyclic aromatic compounds containing a pyridoxamine that carries a phosphate group at the 5'-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pyridoxamines
Direct Parent
Pyridoxamine 5'-phosphates
Alternative Parents
Isoleucine and derivatives / D-alpha-amino acids / Monoalkyl phosphates / Methylpyridines / Hydroxypyridines / Aralkylamines / Heteroaromatic compounds / Amino acids / Monocarboxylic acids and derivatives / Dialkylamines
show 5 more
Substituents
Pyridoxamine 5'-phosphate / Isoleucine or derivatives / Alpha-amino acid / Alpha-amino acid or derivatives / D-alpha-amino acid / Monoalkyl phosphate / Aralkylamine / Methylpyridine / Hydroxypyridine / Organic phosphoric acid derivative
show 20 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
L-valine transaminase activity
Specific Function
Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine. May also function as a transporter of branched chain alpha-keto acids.
Gene Name
BCAT2
Uniprot ID
O15382
Uniprot Name
Branched-chain-amino-acid aminotransferase, mitochondrial
Molecular Weight
44287.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 15:00